Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia
Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However, the effects of intensified regimen on complete remission (CR), relapse and overall survival (OS) remain unknown. We analyzed 1195 patients trea...
Saved in:
| Published in | Blood research Vol. 52; no. 3; pp. 174 - 183 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
01.09.2017
대한혈액학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2287-979X 2288-0011 |
| DOI | 10.5045/br.2017.52.3.174 |
Cover
| Abstract | Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However, the effects of intensified regimen on complete remission (CR), relapse and overall survival (OS) remain unknown.
We analyzed 1195 patients treated with idarubicin plus cytarabine/BHAC (3+7) from 2002 to 2013. Among them, 731 received early intensification with 3-day cytarabine/BHAC (3+10, N=363) or 2-day idarubicin plus cytarabine/BHAC 3 days (5+10, N=368). The 3+10 and 5+10 strategies were applied to patients with bone marrow blast counts of 5-20% and >20% on day 7 of 3+7, respectively.
Early intensification correlated with a younger age (median: 40 vs. 45 yr) and higher t(8;21) frequency (20.4% vs. 7.1%), compared to 3+7. After early intensification, the early death rates were higher among the elderly (3+10 [15.7%], 5+10 [21.7%] vs. 3+7 [6.3%],
=0.038), while the post-induction CR rate was higher in young patients (3+10 [79.8%], 5+10 [75.1%] vs. 3+7 [65.1%],
<0.001). Early relapse rate was also decreased (3+10 [11.8%], 5+10 [11.7%] vs. 3+7 [22.0%],
<0.001). In multivariate analysis, early intensification correlated with an inferior 5-year OS among elderly patients (19.2% vs. 22.8%; hazard ratio [HR]=1.84, 95% confidence interval [CI]; 1.11-3.06,
=0.018) and lower overall relapse rate among young patients (33.0% vs. 41.4%,
=0.023; HR=0.71, 95% CI; 0.55-0.93,
=0.012).
Early intensification correlated with higher CR and lower relapse rates, but not OS in young AML patients. In elderly patients, early intensification correlated with a higher early death rate and poorer OS. |
|---|---|
| AbstractList | Background: Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However, the effects of intensified regimen on complete remission (CR), relapse and overall survival (OS) remain unknown.
Methods: We analyzed 1195 patients treated with idarubicin plus cytarabine/BHAC (3+7) from 2002 to 2013. Among them, 731 received early intensification with 3-day cytar-abine/BHAC (3+10, N=363) or 2-day idarubicin plus cytarabine/BHAC 3 days (5+10, N=368). The 3+10 and 5+10 strategies were applied to patients with bone marrow blast counts of 5‒20% and ＞20% on day 7 of 3+7, respectively.
Results: Early intensification correlated with a younger age (median: 40 vs. 45 yr) and higher t(8;21) frequency (20.4% vs. 7.1%), compared to 3+7. After early intensification, the early death rates were higher among the elderly (3+10 [15.7%], 5+10 [21.7%] vs. 3+7 [6.3%], P=0.038), while the post-induction CR rate was higher in young patients (3+10 [79.8%], 5+10 [75.1%] vs. 3+7 [65.1%], P＜0.001). Early relapse rate was also decreased (3+10 [11.8%], 5+10 [11.7%] vs. 3+7 [22.0%], P＜0.001). In multivariate analysis, early in-tensification correlated with an inferior 5-year OS among elderly patients (19.2% vs. 22.8%; hazard ratio [HR]=1.84, 95% confidence interval [CI]; 1.11‒3.06, P=0.018) and lower overall relapse rate among young patients (33.0% vs. 41.4%, P=0.023; HR=0.71, 95% CI; 0.55‒0.93, P=0.012).
Conclusion: Early intensification correlated with higher CR and lower relapse rates, but not OS in young AML patients. In elderly patients, early intensification correlated with a higher early death rate and poorer OS. KCI Citation Count: 0 Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However, the effects of intensified regimen on complete remission (CR), relapse and overall survival (OS) remain unknown.BACKGROUNDStandard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However, the effects of intensified regimen on complete remission (CR), relapse and overall survival (OS) remain unknown.We analyzed 1195 patients treated with idarubicin plus cytarabine/BHAC (3+7) from 2002 to 2013. Among them, 731 received early intensification with 3-day cytarabine/BHAC (3+10, N=363) or 2-day idarubicin plus cytarabine/BHAC 3 days (5+10, N=368). The 3+10 and 5+10 strategies were applied to patients with bone marrow blast counts of 5-20% and >20% on day 7 of 3+7, respectively.METHODSWe analyzed 1195 patients treated with idarubicin plus cytarabine/BHAC (3+7) from 2002 to 2013. Among them, 731 received early intensification with 3-day cytarabine/BHAC (3+10, N=363) or 2-day idarubicin plus cytarabine/BHAC 3 days (5+10, N=368). The 3+10 and 5+10 strategies were applied to patients with bone marrow blast counts of 5-20% and >20% on day 7 of 3+7, respectively.Early intensification correlated with a younger age (median: 40 vs. 45 yr) and higher t(8;21) frequency (20.4% vs. 7.1%), compared to 3+7. After early intensification, the early death rates were higher among the elderly (3+10 [15.7%], 5+10 [21.7%] vs. 3+7 [6.3%], P=0.038), while the post-induction CR rate was higher in young patients (3+10 [79.8%], 5+10 [75.1%] vs. 3+7 [65.1%], P<0.001). Early relapse rate was also decreased (3+10 [11.8%], 5+10 [11.7%] vs. 3+7 [22.0%], P<0.001). In multivariate analysis, early intensification correlated with an inferior 5-year OS among elderly patients (19.2% vs. 22.8%; hazard ratio [HR]=1.84, 95% confidence interval [CI]; 1.11-3.06, P=0.018) and lower overall relapse rate among young patients (33.0% vs. 41.4%, P=0.023; HR=0.71, 95% CI; 0.55-0.93, P=0.012).RESULTSEarly intensification correlated with a younger age (median: 40 vs. 45 yr) and higher t(8;21) frequency (20.4% vs. 7.1%), compared to 3+7. After early intensification, the early death rates were higher among the elderly (3+10 [15.7%], 5+10 [21.7%] vs. 3+7 [6.3%], P=0.038), while the post-induction CR rate was higher in young patients (3+10 [79.8%], 5+10 [75.1%] vs. 3+7 [65.1%], P<0.001). Early relapse rate was also decreased (3+10 [11.8%], 5+10 [11.7%] vs. 3+7 [22.0%], P<0.001). In multivariate analysis, early intensification correlated with an inferior 5-year OS among elderly patients (19.2% vs. 22.8%; hazard ratio [HR]=1.84, 95% confidence interval [CI]; 1.11-3.06, P=0.018) and lower overall relapse rate among young patients (33.0% vs. 41.4%, P=0.023; HR=0.71, 95% CI; 0.55-0.93, P=0.012).Early intensification correlated with higher CR and lower relapse rates, but not OS in young AML patients. In elderly patients, early intensification correlated with a higher early death rate and poorer OS.CONCLUSIONEarly intensification correlated with higher CR and lower relapse rates, but not OS in young AML patients. In elderly patients, early intensification correlated with a higher early death rate and poorer OS. Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However, the effects of intensified regimen on complete remission (CR), relapse and overall survival (OS) remain unknown. We analyzed 1195 patients treated with idarubicin plus cytarabine/BHAC (3+7) from 2002 to 2013. Among them, 731 received early intensification with 3-day cytarabine/BHAC (3+10, N=363) or 2-day idarubicin plus cytarabine/BHAC 3 days (5+10, N=368). The 3+10 and 5+10 strategies were applied to patients with bone marrow blast counts of 5-20% and >20% on day 7 of 3+7, respectively. Early intensification correlated with a younger age (median: 40 vs. 45 yr) and higher t(8;21) frequency (20.4% vs. 7.1%), compared to 3+7. After early intensification, the early death rates were higher among the elderly (3+10 [15.7%], 5+10 [21.7%] vs. 3+7 [6.3%], =0.038), while the post-induction CR rate was higher in young patients (3+10 [79.8%], 5+10 [75.1%] vs. 3+7 [65.1%], <0.001). Early relapse rate was also decreased (3+10 [11.8%], 5+10 [11.7%] vs. 3+7 [22.0%], <0.001). In multivariate analysis, early intensification correlated with an inferior 5-year OS among elderly patients (19.2% vs. 22.8%; hazard ratio [HR]=1.84, 95% confidence interval [CI]; 1.11-3.06, =0.018) and lower overall relapse rate among young patients (33.0% vs. 41.4%, =0.023; HR=0.71, 95% CI; 0.55-0.93, =0.012). Early intensification correlated with higher CR and lower relapse rates, but not OS in young AML patients. In elderly patients, early intensification correlated with a higher early death rate and poorer OS. |
| Author | Cho, Seok-Goo Kim, Dong-Wook Eom, Ki-Seong Min, Woo-Sung Cho, Byung-Sik Min, Chang-Ki Lee, Seok Kim, Yoo-Jin Lee, Jong Wook Lee, Sung-Eun Min, Gi June Park, Sung-Soo Kim, Hee-Je Yoon, Jae-Ho Kwak, Dae-Hun Jeon, Young-Woo |
| AuthorAffiliation | Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| AuthorAffiliation_xml | – name: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Jae-Ho surname: Yoon fullname: Yoon, Jae-Ho organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 2 givenname: Hee-Je surname: Kim fullname: Kim, Hee-Je organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 3 givenname: Dae-Hun surname: Kwak fullname: Kwak, Dae-Hun organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 4 givenname: Gi June surname: Min fullname: Min, Gi June organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 5 givenname: Sung-Soo surname: Park fullname: Park, Sung-Soo organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 6 givenname: Young-Woo surname: Jeon fullname: Jeon, Young-Woo organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 7 givenname: Sung-Eun surname: Lee fullname: Lee, Sung-Eun organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 8 givenname: Byung-Sik surname: Cho fullname: Cho, Byung-Sik organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 9 givenname: Ki-Seong surname: Eom fullname: Eom, Ki-Seong organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 10 givenname: Yoo-Jin surname: Kim fullname: Kim, Yoo-Jin organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 11 givenname: Seok surname: Lee fullname: Lee, Seok organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 12 givenname: Chang-Ki surname: Min fullname: Min, Chang-Ki organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 13 givenname: Seok-Goo surname: Cho fullname: Cho, Seok-Goo organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 14 givenname: Dong-Wook surname: Kim fullname: Kim, Dong-Wook organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 15 givenname: Jong Wook surname: Lee fullname: Lee, Jong Wook organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 16 givenname: Woo-Sung surname: Min fullname: Min, Woo-Sung organization: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29043232$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002263049$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1kt9rFDEQxxep2Fr77pPkUZFds8km2bwI5fBHoSBIBd9CNjvx4u0mZ5Kt3J_hf2zurhUrmIfMhPl8v0OYeVqd-OChqp63uGG4Y2-G2BDcioaRhjat6B5VZ4T0fY1x254cclFLIb-eVhcpfcfl9EJIwp5Up0TijhJKzqpfqzBvdXQpeBQsymtAYC2YnPZP0HHaIecz-OSsg7Hk42KyK7RZwxwKH_V2h7QfUcrl1nFE9LV4WHUe6XGZMtrq7MAX758ur5E2SwY072AKbkQTLBuYnX5WPbZ6SnBxF8-rL-_f3aw-1tefPlytLq9r01Gca9FTzDXlAlNtRNtz0Jzw1g6cSAuUE2asGUfBDWWSdz2TvR3wiGXXU8N5T8-rV0dfH63aGKeCdof4LahNVJefb64UwaSXmBT27ZHdLsMMoyl_iHpS2-hmHXcH5cOKd-vic6sY71qGZTF4eWcQw48FUlazSwamSXsIS1KtZISVqTBa0Bd_9_rT5H5mBeBHwMSQUgSrjMt6P5PS2k2qxWq_H2qIar8fihFFVdmPIsT_CO-9_yv5DedDv5s |
| CitedBy_id | crossref_primary_10_1186_s13045_018_0611_7 crossref_primary_10_3389_fonc_2023_1281782 crossref_primary_10_1111_tan_13966 crossref_primary_10_1182_blood_2021013671 crossref_primary_10_3390_jcm12185940 crossref_primary_10_3389_fpsyg_2023_1045031 crossref_primary_10_54393_pjhs_v5i06_1570 crossref_primary_10_1016_j_bbmt_2018_04_020 |
| Cites_doi | 10.1056/NEJMoa0904544 10.1016/j.bbmt.2012.04.008 10.1038/sj.bmt.1704556 10.1200/JCO.2009.23.2652 10.1007/BF02934571 10.1182/blood-2015-07-657403 10.1200/JCO.1996.14.1.204 10.1016/j.bbmt.2017.01.070 10.1182/blood-2002-02-0532 10.1214/aos/1176350951 10.1016/j.bbmt.2014.09.029 10.1182/blood.V88.8.2841.bloodjournal8882841 10.1056/NEJM199909303411407 10.1007/s12185-010-0649-y 10.1182/blood-2015-01-623447 10.3109/10428199809092687 10.1002/ajh.24271 10.18632/oncotarget.15295 10.1056/NEJMoa1010222 10.1200/JCO.2013.51.8571 10.1056/NEJM199410063311402 10.1182/blood.V87.5.1710.1710 10.1111/bjh.12233 10.1182/blood-2011-06-361410 |
| ContentType | Journal Article |
| Copyright | 2017 Korean Society of Hematology 2017 Korean Society of Hematology |
| Copyright_xml | – notice: 2017 Korean Society of Hematology 2017 Korean Society of Hematology |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.5045/br.2017.52.3.174 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2288-0011 |
| EndPage | 183 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_2028902 PMC5641509 29043232 10_5045_br_2017_52_3_174 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; – fundername: ; grantid: 2015R1D1A1A01059819 |
| GroupedDBID | 0R~ 5-W 8JR 8XY 9ZL AAJSJ AAKKN AASML AAYXX ABEEZ ACACY ACULB ADBBV ADRAZ AFGXO ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL C24 C6C CITATION DIK EBLON EF. FRP HYE KQ8 M48 PGMZT RPM SOJ W2D NPM 7X8 5PM ACYCR M~E OK1 |
| ID | FETCH-LOGICAL-c430t-78306a36703ac7186ea6261fb629fe3625cfcdd76c359648598fb0d09483c6683 |
| IEDL.DBID | M48 |
| ISSN | 2287-979X |
| IngestDate | Sun Jan 21 03:11:41 EST 2024 Thu Aug 21 18:13:31 EDT 2025 Fri Jul 11 14:25:26 EDT 2025 Mon Jul 21 06:05:47 EDT 2025 Thu Apr 24 23:00:04 EDT 2025 Tue Jul 01 01:58:59 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Acute myeloid leukemia Early intensification Induction chemotherapy |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c430t-78306a36703ac7186ea6261fb629fe3625cfcdd76c359648598fb0d09483c6683 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.5045/br.2017.52.3.174 |
| PMID | 29043232 |
| PQID | 1952529053 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_2028902 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5641509 proquest_miscellaneous_1952529053 pubmed_primary_29043232 crossref_citationtrail_10_5045_br_2017_52_3_174 crossref_primary_10_5045_br_2017_52_3_174 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-01 |
| PublicationDateYYYYMMDD | 2017-09-01 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Blood research |
| PublicationTitleAlternate | Blood Res |
| PublicationYear | 2017 |
| Publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 대한혈액학회 |
| Publisher_xml | – name: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis – name: 대한혈액학회 |
| References | Li (10.5045/br.2017.52.3.174_ref13) 2014; 9 Cho (10.5045/br.2017.52.3.174_ref18) 2012; 18 Gray (10.5045/br.2017.52.3.174_ref22) 1988; 16 Kimura (10.5045/br.2017.52.3.174_ref23) 1986; 3 Haferlach (10.5045/br.2017.52.3.174_ref26) 2004; 89 Fernandez (10.5045/br.2017.52.3.174_ref4) 2009; 361 Park (10.5045/br.2017.52.3.174_ref15) 1996; 33 Willemze (10.5045/br.2017.52.3.174_ref12) 2014; 32 Teuffel (10.5045/br.2017.52.3.174_ref3) 2013; 161 Burnett (10.5045/br.2017.52.3.174_ref6) 2015; 125 Mayer (10.5045/br.2017.52.3.174_ref28) 1994; 331 Shaffer (10.5045/br.2017.52.3.174_ref14) 2009 Kobayashi (10.5045/br.2017.52.3.174_ref24) 1996; 14 Pautas (10.5045/br.2017.52.3.174_ref7) 2010; 28 Bishop (10.5045/br.2017.52.3.174_ref11) 1998; 28 Campuzano-Zuluaga (10.5045/br.2017.52.3.174_ref25) 2016; 91 10.5045/br.2017.52.3.174_ref2 Löwenberg (10.5045/br.2017.52.3.174_ref1) 1999; 341 Yoon (10.5045/br.2017.52.3.174_ref17) 2017; 23 Kern (10.5045/br.2017.52.3.174_ref27) 2003; 101 Lee (10.5045/br.2017.52.3.174_ref5) 2011; 118 Weick (10.5045/br.2017.52.3.174_ref9) 1996; 88 Lee (10.5045/br.2017.52.3.174_ref20) 2010; 92 Yoon (10.5045/br.2017.52.3.174_ref16) 2017; 8 Luskin (10.5045/br.2017.52.3.174_ref8) 2016; 127 Kim (10.5045/br.2017.52.3.174_ref19) 2004; 34 Fukushima (10.5045/br.2017.52.3.174_ref29) 2012; 32 Bishop (10.5045/br.2017.52.3.174_ref10) 1996; 87 Yahng (10.5045/br.2017.52.3.174_ref21) 2015; 21 Löwenberg (10.5045/br.2017.52.3.174_ref30) 2011; 364 |
| References_xml | – volume: 361 start-page: 1249 year: 2009 ident: 10.5045/br.2017.52.3.174_ref4 publication-title: N Engl J Med doi: 10.1056/NEJMoa0904544 – volume: 18 start-page: 1552 year: 2012 ident: 10.5045/br.2017.52.3.174_ref18 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2012.04.008 – volume: 34 start-page: 215 year: 2004 ident: 10.5045/br.2017.52.3.174_ref19 publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1704556 – volume: 28 start-page: 808 year: 2010 ident: 10.5045/br.2017.52.3.174_ref7 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.2652 – volume: 33 start-page: 24 issue: 4 Suppl 3 year: 1996 ident: 10.5045/br.2017.52.3.174_ref15 publication-title: Semin Hematol – volume: 3 start-page: 15 year: 1986 ident: 10.5045/br.2017.52.3.174_ref23 publication-title: Med Oncol Tumor Pharmacother doi: 10.1007/BF02934571 – volume: 127 start-page: 1551 year: 2016 ident: 10.5045/br.2017.52.3.174_ref8 publication-title: Blood doi: 10.1182/blood-2015-07-657403 – volume: 14 start-page: 204 year: 1996 ident: 10.5045/br.2017.52.3.174_ref24 publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.1.204 – volume: 23 start-page: 588 year: 2017 ident: 10.5045/br.2017.52.3.174_ref17 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2017.01.070 – volume: 101 start-page: 64 year: 2003 ident: 10.5045/br.2017.52.3.174_ref27 publication-title: Blood doi: 10.1182/blood-2002-02-0532 – volume: 16 start-page: 1141 year: 1988 ident: 10.5045/br.2017.52.3.174_ref22 publication-title: Ann Stat doi: 10.1214/aos/1176350951 – volume: 21 start-page: 119 year: 2015 ident: 10.5045/br.2017.52.3.174_ref21 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2014.09.029 – volume: 88 start-page: 2841 year: 1996 ident: 10.5045/br.2017.52.3.174_ref9 publication-title: Blood doi: 10.1182/blood.V88.8.2841.bloodjournal8882841 – volume: 341 start-page: 1051 year: 1999 ident: 10.5045/br.2017.52.3.174_ref1 publication-title: N Engl J Med doi: 10.1056/NEJM199909303411407 – volume: 89 start-page: 408 year: 2004 ident: 10.5045/br.2017.52.3.174_ref26 publication-title: Haematologica – volume: 32 start-page: 643 year: 2012 ident: 10.5045/br.2017.52.3.174_ref29 publication-title: Anticancer Res – volume: 92 start-page: 342 year: 2010 ident: 10.5045/br.2017.52.3.174_ref20 publication-title: Int J Hematol doi: 10.1007/s12185-010-0649-y – volume: 9 year: 2014 ident: 10.5045/br.2017.52.3.174_ref13 publication-title: PLoS One – volume: 125 start-page: 3878 year: 2015 ident: 10.5045/br.2017.52.3.174_ref6 publication-title: Blood doi: 10.1182/blood-2015-01-623447 – volume: 28 start-page: 315 year: 1998 ident: 10.5045/br.2017.52.3.174_ref11 publication-title: Leuk Lymphoma doi: 10.3109/10428199809092687 – volume: 91 start-page: 277 year: 2016 ident: 10.5045/br.2017.52.3.174_ref25 publication-title: Am J Hematol doi: 10.1002/ajh.24271 – volume: 8 start-page: 41590 year: 2017 ident: 10.5045/br.2017.52.3.174_ref16 publication-title: Oncotarget doi: 10.18632/oncotarget.15295 – volume: 364 start-page: 1027 year: 2011 ident: 10.5045/br.2017.52.3.174_ref30 publication-title: N Engl J Med doi: 10.1056/NEJMoa1010222 – volume: 32 start-page: 219 year: 2014 ident: 10.5045/br.2017.52.3.174_ref12 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.51.8571 – volume: 331 start-page: 896 year: 1994 ident: 10.5045/br.2017.52.3.174_ref28 publication-title: N Engl J Med doi: 10.1056/NEJM199410063311402 – ident: 10.5045/br.2017.52.3.174_ref2 – volume: 87 start-page: 1710 year: 1996 ident: 10.5045/br.2017.52.3.174_ref10 publication-title: Blood doi: 10.1182/blood.V87.5.1710.1710 – volume: 161 start-page: 192 year: 2013 ident: 10.5045/br.2017.52.3.174_ref3 publication-title: Br J Haematol doi: 10.1111/bjh.12233 – volume-title: ISCN 2009: An International System for Human Cytogenetic Nomenclature year: 2009 ident: 10.5045/br.2017.52.3.174_ref14 – volume: 118 start-page: 3832 year: 2011 ident: 10.5045/br.2017.52.3.174_ref5 publication-title: Blood doi: 10.1182/blood-2011-06-361410 |
| SSID | ssj0000877925 |
| Score | 2.093194 |
| Snippet | Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However,... Background: Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML).... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 174 |
| SubjectTerms | Original 병리학 |
| Title | Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29043232 https://www.proquest.com/docview/1952529053 https://pubmed.ncbi.nlm.nih.gov/PMC5641509 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002263049 |
| Volume | 52 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Blood Research, 2017, 52(3), , pp.174-183 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfYkBAvaHwubEwG8YJQuiS2Y_sJoYlpII0nKvXN8idEbRNIW2n9M_Yf75ykhaIKiYcoieMkis_x_c53_h1Cb73PpPCGpZ4FmlJDbKqFjavRAhFaEGJoXCh8_bW8GtMvEzb5vTx6aMDFXtMu5pMat7PRza_1B_jhAb-OGCCScxN5PXM-YsWIxACdA3S_8xbFQL4B7HfjsuBcdllYCzATUsnlpPdb7n3Ijp46qNuwD4L-HUn5h2q6PEKPBkyJP_ad4DG65-sn6MH14DV_im4vtskGcRMwQD48hHHEUx8pjnHVh7IHQKRw7HpOWQwSnQ9LtNZY1w5vZh4wec93r1Y17rg88MDUusBxihdru1p6PF_7WVM5PPOrqZ9X-hkaX376dnGVDqkYUktJtky5ANNCR7I3oi2os9JrsITyYMpCBg9KkNlgneOlJUyWVDApgskc2I6C2LIU5Dk6rJvaHyMMpU6H3HFBCbUuMyaHjYcgrBUZCwk63zS8sgNPeUyXMVNgr0RRKdOqKCrFCkUUiCpB77Z3_Ow5Ov5R9w3IUk1tpSKxdtx_b9S0VWA-fIaqnd81Qa83olbwt0UXiq59s1qoXLKCFRJGrgS96EW_fSUUUwIANUF8p1NsK8QX7l6pqx8dozcrAUdl8uV_fMgJehjP-3C3U3S4bFf-FeCjpTnruv1ZN3F1B-jsD5E |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+effects+of+early+intensified+induction+chemotherapy+and+standard+3%2B7+chemotherapy+in+adult+patients+with+acute+myeloid+leukemia&rft.jtitle=Blood+research&rft.au=Yoon%2C+Jae-Ho&rft.au=Kim%2C+Hee-Je&rft.au=Kwak%2C+Dae-Hun&rft.au=Min%2C+Gi+June&rft.date=2017-09-01&rft.issn=2287-979X&rft.eissn=2288-0011&rft.volume=52&rft.issue=3&rft.spage=174&rft_id=info:doi/10.5045%2Fbr.2017.52.3.174&rft.externalDBID=n%2Fa&rft.externalDocID=10_5045_br_2017_52_3_174 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2287-979X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2287-979X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2287-979X&client=summon |